Clinical Trial: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months

U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505810) titled 'Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months' on March 13.

Brief Summary: The goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety of a booster dose administered at 12 months of age, in healthy children aged 3 to 5 months.

The main questions it aims to answer are:

Is the immune response induced by the primary series of the investigational vaccine non-inferior to that of the licensed control vaccine? What is th...